🇺🇸 Multiple-Visit-"Corticosteroid Paste" in United States

FDA authorised Multiple-Visit-"Corticosteroid Paste" on 12 July 2002

Marketing authorisations

FDA — authorised 12 July 2002

  • Application: ANDA040256
  • Marketing authorisation holder: PH HEALTH
  • Status: supplemented

FDA — authorised 8 April 2005

  • Application: NDA021737
  • Marketing authorisation holder: BAUSCH AND LOMB
  • Status: supplemented

FDA — authorised 25 April 2016

  • Application: ANDA090982
  • Marketing authorisation holder: RISING
  • Status: approved

FDA — authorised 20 November 2019

  • Application: ANDA210198
  • Marketing authorisation holder: CADILA
  • Status: approved

FDA — authorised 17 October 2025

  • Application: ANDA218601
  • Marketing authorisation holder: ALEMBIC
  • Status: approved

FDA

  • Status: approved

Multiple-Visit-"Corticosteroid Paste" in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Multiple-Visit-"Corticosteroid Paste" approved in United States?

Yes. FDA authorised it on 12 July 2002; FDA authorised it on 8 April 2005; FDA authorised it on 25 April 2016.

Who is the marketing authorisation holder for Multiple-Visit-"Corticosteroid Paste" in United States?

PH HEALTH holds the US marketing authorisation.